pirfenidone sustained release (EXCL-100)
/ Excalibur Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 14, 2022
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Excalibur Pharmaceuticals, Inc. | Recruiting ➔ Completed
Trial completion • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
August 25, 2022
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Excalibur Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
June 22, 2022
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Excalibur Pharmaceuticals, Inc.
New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1